Ayurveda interventions for rheumatoid arthritis

Tillu, Girish; Chopra, Arvind; Sarmukaddam, Sanjeev; Tharyan, Prathap

doi:10.1002/14651858.cd011569

Cited by 4 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of Ayurvedic treatment for rheumatoid arthritis was observed through a cross-sectional experiential longitudinal study [ 35 ]. A Cochrane protocol for systemic review of Ayurvedic interventions in RA has also been published [ 36 ]. A systematic review of Ayurvedic medicine for rheumatoid arthritis conducted in 2005 observed a paucity of RCTs of Ayurvedic medicines for RA.…”

Section: Discussionmentioning

confidence: 99%

Clinical metabolomics investigation of rheumatoid arthritis patients receiving ayurvedic whole system intervention

Rastogi,

Verma,

Trivedi

et al. 2024

Journal of Ayurveda and Integrative Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical metabolomics investigation of rheumatoid arthritis patients receiving ayurvedic whole system intervention

Rastogi,

Verma,

Trivedi

et al. 2024

Journal of Ayurveda and Integrative Medicine

View full text Add to dashboard Cite

“…Each of the included trials will be assessed for risk of bias in the following domains: sequence generation, allocation concealment, blinding (separately assessed for blinding of participants and personnel and for blinding of outcome assessors), incomplete outcome data, selective outcome reporting, and other biases (relating to particular aspects of study design and conflicts of interest). 28 For each of these components, a judgment will be assigned between the authors regarding the risk of bias of high, low, or unclear. The judgments will be recorded and justifications in "risk of bias" tables accompanying the characteristics of the included studies will be analyzed and findings will be summarized in a risk of bias summary graph and figure.…”

Section: Assessment Of Risk Of Bias In Included Studiesmentioning

confidence: 99%

Ayurvedic Management of Fistula in Ano

Shankar¹,

Deepthi²,

Rohit³

et al. 2019

Journal of Research in Ayurvedic Sciences

View full text Add to dashboard Cite

Introduction: Fistula in ano is considered to be complicated and vicious due to its nature of recurrences and exacerbations. Ayurveda includes this disease under the list of AstaMahagada (eight serious diseases that are difficult to treat by nature itself ) due to this attribute. Ayurvedic literature offers various effective and safe management strategies for fistula in ano. Several works have been conducted to prove the efficacy and effectiveness of various treatment modalities mentioned in Ayurvedic texts. Kshara sutra, Kshara karma, Agnikarma, and Ksharavarti are a few to name in this list. A lacuna exists in not analyzing or compiling these works. Hence, the purpose of this systematic review is to generate evidence for efficacy, effectiveness, and safety profile of Ayurvedic interventions in the management of fistula in ano. Materials and methods: Electronic search from various online databases and clinical trial registers will be done. Manual search for gray literatures will be done from various colleges and universities. There will be no language restrictions. Three authors independently will screen all citations and abstracts to identify potentially eligible trials. Based on the inclusion criteria, full articles will be evaluated and disagreements will be discussed among the three authors. Data extraction from the included studies will be done by the three reviewers independently with extraction forms containing methods, participants, interventions, comparators/controls, and outcomes. Each of the included trials will be assessed for risk of bias. Primary data analysis will be done for both qualitative and quantitative data. Heterogeneity among trials will be assessed by inspecting forest plots. If heterogeneity is detected, and it is still considered clinically meaningful to combine studies, a randomeffects model will be used. Meta-analysis will be done for pooled estimates and others would be presented as narrative synthesis and shall be represented in tabular and graphical forms. Dissemination: The systematic review will be published in a peer-reviewed journal. It will also be disseminated electronically and in print. The review may guide healthcare practices and policy framing regarding the treatment of fistula in ano with Ayurvedic interventions. Study registration: PROSPERO registration no. CRD42019131911.

show abstract

“…Several research publications have attempted to unearth scientific evidence of efficacy of Ayurveda derived drugs to treat arthritis [7] , [8] , [9] , [10] , [11] , [12] , [13] . Cochrane reviews include a protocol on validation of Ayurvedic drugs in the treatment of RA [14] , [15] .…”

Section: Introductionmentioning

confidence: 99%

Long term effectiveness of RA-1 as a monotherapy and in combination with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis

Chopra¹,

Saluja²,

Kianifard³

et al. 2018

Journal of Ayurveda and Integrative Medicine

Self Cite

View full text Add to dashboard Cite

Background: Data on long term use of Ayurvedic drugs is sparse. They may prove useful if combined with modern medicine in certain clinical situations (integrative medicine). We present the results of a long term observational study of RA-1 (Ayurvedic drug) used in the treatment of rheumatoid arthritis (RA).ObjectiveThe objective was to study safety of long term use of RA-1 for treatment of rheumatoid arthritis (RA).Materials and methodsOn completion of a 16 week randomized controlled study, 165 consenting volunteer patients were enrolled into a three year open label phase (OLP) study. Patients were symptomatic with persistent active disease and naïve for disease modifying anti-rheumatic drugs (DMARD). 57 patients were on fixed low dose prednisone. Patients were examined every 10–14 weeks in a routine rheumatology practice using standard care norms. They continued RA-1 (Artrex ™, 2 tablets twice daily) throughout the study period and were generally advised to lead a healthy life style. Based on clinical judgment, rheumatologist added DMARD and/or steroids (modified if already in use) to patients with inadequate response; chloroquine and/or methotrexate commonly used. Treatment response was assessed using American College of Rheumatology (ACR) efficacy measures and ACR 20% improvement index standard update statistical software (SAS and SPSS) were used; significant at p < 0.05.Results158, 130 and 122 patients respectively completed evaluations at 1, 2 and 3 year primary end point. The ACR 20 response (range 34–40%) remained stable over three years (p = 0.33). Patients improved optimum for several measures by one year (p < 0.05) and this was sustained. The use of steroids varied from 42 to 49% patients at yearly end points (mean daily dose 5 mg prednisone); correspondingly the use of DMARD varied from 20 to 34% patients. 40% patients on RA-1 did not require DMARD/steroids for control of disease. 77% patients reported adverse events, albeit mild and mostly gut related, and not causing withdrawal. Several study limitations (especially self-selection) were reduced by the high patient retention and consistency in drug use.ConclusionRA-1 is safe and effective in the long term management of symptomatic active chronic RA. DMARDs and/or steroids can be used judiciously along with RA-1 to treat difficult disease/flares. Further studies are required to evaluate RA-1 in early RA. This paves way for research and application of integrative therapeutic approach in clinical medicine.

show abstract

Ayurveda interventions for rheumatoid arthritis

Cited by 4 publications

References 76 publications

Clinical metabolomics investigation of rheumatoid arthritis patients receiving ayurvedic whole system intervention

Clinical metabolomics investigation of rheumatoid arthritis patients receiving ayurvedic whole system intervention

Ayurvedic Management of Fistula in Ano

Long term effectiveness of RA-1 as a monotherapy and in combination with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis

Contact Info

Product

Resources

About